US Bancorp’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-3,545
| Closed | -$208K | – | 4157 |
|
|
2023
Q4 | $208K | Buy |
3,545
+178
| +5% | +$10K | ﹤0.01% | 1987 |
|
|
2023
Q3 | $147K | Buy |
3,367
+2,272
| +207% | +$81.1K | ﹤0.01% | 1968 |
|
|
2023
Q2 | $39.6K | Sell |
1,095
-1,760
| -62% | -$72.5K | ﹤0.01% | 2621 |
|
|
2023
Q1 | $106K | Buy |
2,855
+1,014
| +55% | +$45.6K | ﹤0.01% | 2156 |
|
|
2022
Q4 | $83.4K | Sell |
1,841
-2,097
| -53% | -$136K | ﹤0.01% | 2274 |
|
|
2022
Q3 | $275K | Buy |
3,938
+569
| +17% | +$42.1K | ﹤0.01% | 1689 |
|
|
2022
Q2 | $227K | Buy |
3,369
+1,471
| +78% | +$93.5K | ﹤0.01% | 1829 |
|
|
2022
Q1 | $156K | Buy |
1,898
+1,478
| +352% | +$151K | ﹤0.01% | 2078 |
|
|
2021
Q4 | $63K | Sell |
420
-68
| -14% | -$10.6K | ﹤0.01% | 2528 |
|
|
2021
Q3 | $86K | Buy |
488
+216
| +79% | +$34.8K | ﹤0.01% | 2380 |
|
|
2021
Q2 | $44K | Buy |
272
+115
| +73% | +$18.5K | ﹤0.01% | 2737 |
|
|
2021
Q1 | $27K | Buy |
157
+72
| +85% | +$14.3K | ﹤0.01% | 2894 |
|
|
2020
Q4 | $19K | Buy |
85
+72
| +554% | +$15.6K | ﹤0.01% | 2946 |
|
|
2020
Q3 | $2K | Buy |
+13
| New | +$1.78K | ﹤0.01% | 3533 |
|
|
2020
Q1 | – | Sell |
-44
| Closed | -$6K | – | 3833 |
|
|
2019
Q4 | $6K | Sell |
44
-8
| -15% | -$772 | ﹤0.01% | 3251 |
|
|
2019
Q3 | $4K | Sell |
52
-172
| -77% | -$16.1K | ﹤0.01% | 3307 |
|
|
2019
Q2 | $23K | Buy |
224
+62
| +38% | +$4.83K | ﹤0.01% | 2831 |
|
|
2019
Q1 | $12K | Buy |
+162
| New | +$11K | ﹤0.01% | 3015 |
|
Other funds holding MRTX
US Bancorp's MRTX Position: Q1 2024 in Review
US Bancorp sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 3,545 shares — an estimated $208K sold.
US Bancorp first reported a position in MRTX in Q1 2019 and held it in 18 quarters. The position peaked at $275K in Q3 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- US Bancorp reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- US Bancorp sold 3,545 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $208K.
- US Bancorp first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 18 quarters.
- US Bancorp's Mirati Therapeutics, Inc. Common Stock position peaked at $275K in Q3 2022.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on US Bancorp's 13F filing for Q1 2024, filed 8 May 2024.